^(153)Sm-CEA单抗对结肠癌移植瘤裸鼠模型放射免疫治疗的实验研究(英文)

Radioimmunotherapy with ^(153)Sm-CEA monoclonal antibody in nude mice bearing human colon carcinoma:an experimental study

目的观察153Sm标记抗CEA单抗(153Sm-CEA mAb)对肿瘤的抑制效应,探索153Sm-CEA mAb在荷人结肠癌移植瘤裸鼠模型中的放射免疫治疗作用。方法体外培养的LoVo细胞株无菌接种于15只裸鼠前肢皮下,制备荷人结肠癌移植瘤裸鼠模型并分为3组,每组5只。在移植瘤接种后的第3天实施治疗,采用单次较大剂量治疗(11.1 MBq/每鼠),治疗组注射153Sm标记(DTPA环酐法)抗CEA单抗,单纯注射153SmCl3的荷瘤裸鼠作为治疗对照组,非治疗对照组注射100 μl 生理盐水。给药后定期测量裸鼠的体质量和肿瘤生长体积并进行肿瘤的组织病理学观察。结果153Sm-CEA mAb治疗组对肿瘤有明显的抑制作用,治疗第4周肿瘤生长抑制率达到74.29%,而非治疗对照组肿瘤体积增长迅速。治疗对照组第4周肿瘤生长抑制率为15.90%,与治疗组相比有显著性差异(P<0.05)。治疗组与对照组相比,动物体质量没有显著性差异。组织病理学结果提示153Sm-CEA mAb治疗组肿瘤组织有坏死改变,而对照组肿瘤细胞呈典型的癌细胞形态。结论153Sm-CEA mAb对人结肠癌的荷瘤裸鼠具有抑制增长作用。153Sm-CEA mAb作为一种新型核素的导向治疗剂,具有定位诊断和导向治疗结肠癌的双重作用,具有良好的应用前景。

Objective To observe the therapeutic effect of 153 Sm-labeled CEA monodonal antibody(mAb) in nude mice bearing human colon carcinoma. Methods Fifteen nude mice were subjected to subcutaneous inoculation of human colon carcinoma cells, and 3 days later, they were divided into 3 groups with equal numbers to receive single high-dose injection of 11.1 MBq 153Sm-CEA mAb (therapy group), 11.1MBq 153 SmCl 3 (therapy control group), or 100 μl normal saline (non-treatment control group). The tumor-inhibiting effect of 153 Sm-labeled CEA mAb was evaluated in terms of body weight changes and tumor volume variation 4 weeks after the treatment. Histological analysis of tumors were performed in all the groups after the all other observations were completed. Results 153 Sm-CEA mAb had a significant anti-tumor effect, with a tumor inhibition rate of 74.29% at 4 weeks after treatment, while for 153 SmCl 3 , the inhibition rate was only 15.90%. Rapid tumor growth was observed in non-treatment control group. No significant difference in the body weight changes was noted between the 3 groups. Histopathological examination revealed tumor necrosis as the evidence for radioactive damage in therapy group, which was not observed in non-treatment control group. Conclusions 153 Sm-CEA mAb has a strong selective inhibitory effect against colon carcinoma and may be potentially used as an agent in radioimmunotherapy.